The decision to add this role to the executive management team underlines the company's growth ambitions and goal to sustainably contribute to the expansion of its product portfolio as well as the provision of new healthcare solutions by investing in its innovation and development capabilities.
Lucia Cinque, who holds a PhD in Biomedical Engineering, brings experience from senior positions in R&D and innovation management of healthcare technology companies; most recently she was co-founder of a startup in this sector. In her positions, she dealt in depth with innovative growth opportunities and their translation into viable business models.
Prof. Dr. Roderich C. Thümmel, Chairman of the Advisory Board, warmly welcomes Lucia Cinque on behalf of the Advisory Board: "We are pleased to win such a proven innovator and experienced manager for the Wörwag’s Management Board in Ms. Cinque. We are convinced that she will raise Wörwag's innovation agenda to a new level. This will help to expand our product portfolio, maintain our market leadership in biofactors and further foster the innovation mindset in our organization."
Company profile
Woerwag Pharma GmbH & Co. KG is a family-owned, pharmaceutical company headquartered in Boeblingen, Germany, developing and selling biofactor preparations wordwide. The company’s product rage is exclusively available in pharmacies and includes both prescription preparations as well as over the counter (OTC) products and food supplements. Therapeutic areas focus on diabetes and associated diseases, nervous system and musculo-skeletal system.
In 2020, the company achieved a sales revenue of more than 235 million euros with 1000 employees in more than 35 countries. This year, the company celebrates its 50th anniversary.
Press Contact
Woerwag Pharma GmbH & Co. KG
Tanja Thoma-Ly
Corporate Communications
Phone: 07031 62 04-338
tanja.thoma-ly(at)woerwagpharma.com
